PTC Therapeutics (PTCT) – Investment Analysts’ Weekly Ratings Changes

PTC Therapeutics (NASDAQ: PTCT) has recently received a number of price target changes and ratings updates:

• 10/16/2026 – PTC Therapeutics is now covered by Truist Financial Corporation. They set a “hold” rating and a $62.00 price target on the stock.
• 10/15/2026 – PTC Therapeutics had its “buy” rating reaffirmed by UBS Group AG. They now have a $90.00 price target on the stock, up from $80.00.
• 10/10/2026 – PTC Therapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 10/8/2026 – PTC Therapeutics was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 10/7/2026 – PTC Therapeutics had its price target lowered by Royal Bank Of Canada from $85.00 to $75.00. They now have a “sector perform” rating on the stock.
• 9/22/2026 – PTC Therapeutics had its price target raised by Cantor Fitzgerald from $130.00 to $137.00. They now have an “overweight” rating on the stock.
• 9/19/2026 – PTC Therapeutics was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 9/17/2026 – PTC Therapeutics was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 9/14/2026 – PTC Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $98.00 price target on the stock.
• 9/1/2026 – PTC Therapeutics was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 8/22/2026 – PTC Therapeutics was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 8/17/2026 – PTC Therapeutics was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.

Insider Activity at PTC Therapeutics

In other PTC Therapeutics news, CEO Matthew B. Klein sold 10,292 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $68.57, for a total value of $705,722.44. Following the transaction, the chief executive officer directly owned 383,868 shares in the company, valued at $26,321,828.76. The trade was a 2.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Mark Boulding sold 435 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $64.16, for a total transaction of $27,909.60. Following the transaction, the vice president directly owned 105,272 shares of the company’s stock, valued at $6,754,251.52. This represents a 0.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 74,870 shares of company stock worth $5,173,236. Insiders own 5.30% of the company’s stock.

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs use technologies designed to address genetic and molecular causes of disease, including RNA biology, protein translation and gene therapy.

The company’s commercial portfolio includes Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency in eligible patients.